Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREAS SCHMID

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962663377
CMS profile
761022
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$7,244.44

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Insmed, Inc. $7,244.44 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREAS SCHMID

NPI 1962663377 · CMS profile ID 761022

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962663377?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962663377?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962663377?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1962663377?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $7,244.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $2.2108/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739686817 CMS
Insmed, Inc. $126.8902/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691761 CMS
Insmed, Inc. $2,475.0002/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739693425 CMS
Insmed, Inc. $3,825.0002/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739692631 CMS
Insmed, Inc. $116.0702/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739694443 CMS
Insmed, Inc. $270.0702/07/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691675 CMS
Insmed, Inc. $425.1001/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739693571 CMS
Insmed, Inc. $1.0501/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739683439 CMS
Insmed, Inc. $3.0501/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739683589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,930.13 21
PY2020 $7,244.44 9
PY2023 $1,117.56 9
PY2024 $15.37 1
PY2025 $72.62 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,654.12 9
PY2025 Principal investigator $330,468.44 168
PY2024 Principal investigator $383,470.04 191
PY2023 Principal investigator $688,078.36 235
PY2022 Principal investigator $419,549.56 143
PY2021 Principal investigator $95,534.58 57
PY2019 Principal investigator $7,217.27 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

235 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $745.00 12/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774885
Principal investigator 1 Insmed, Inc. $665.00 12/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774933
Principal investigator 1 Insmed, Inc. $1,626.70 12/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776545
Principal investigator 1 Insmed, Inc. $2.53 12/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770129
Principal investigator 1 Insmed, Inc. $400.00 11/29/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770061
Principal investigator 1 Insmed, Inc. $53.40 11/29/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770177
Principal investigator 1 Insmed, Inc. $93.45 11/29/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770641
Principal investigator 1 Insmed, Inc. $600.00 11/29/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776569
Principal investigator 1 Insmed, Inc. $53.40 11/29/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776579
Principal investigator 1 Insmed, Inc. $10,029.15 11/06/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770067
Principal investigator 1 Insmed, Inc. $0.46 11/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770043
Principal investigator 1 Insmed, Inc. $1.27 11/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770131
Principal investigator 1 Insmed, Inc. $33.38 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774883
Principal investigator 1 Insmed, Inc. $20.03 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774899
Principal investigator 1 Insmed, Inc. $133.50 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774901
Principal investigator 1 Insmed, Inc. $667.50 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774903
Principal investigator 1 Insmed, Inc. $50.73 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774905
Principal investigator 1 Insmed, Inc. $267.00 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774913
Principal investigator 1 Insmed, Inc. $60.08 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774915
Principal investigator 1 Insmed, Inc. $39.67 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774923
Principal investigator 1 Insmed, Inc. $200.25 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774925
Principal investigator 1 Insmed, Inc. $667.50 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774937
Principal investigator 1 Insmed, Inc. $20.03 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774939
Principal investigator 1 Insmed, Inc. $37.38 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774943
Principal investigator 1 Insmed, Inc. $200.25 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774949
Principal investigator 1 Insmed, Inc. $39.67 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774953
Principal investigator 1 Insmed, Inc. $44.06 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774969
Principal investigator 1 Insmed, Inc. $60.08 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774971
Principal investigator 1 Insmed, Inc. $30.71 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780983
Principal investigator 1 Insmed, Inc. $133.50 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780985
Principal investigator 1 Insmed, Inc. $37.38 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780987
Principal investigator 1 Insmed, Inc. $196.91 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780989
Principal investigator 1 Insmed, Inc. $20.03 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780993
Principal investigator 1 Insmed, Inc. $30.71 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781003
Principal investigator 1 Insmed, Inc. $53.40 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781011
Principal investigator 1 Insmed, Inc. $50.73 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781015
Principal investigator 1 Insmed, Inc. $174.89 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781017
Principal investigator 1 Insmed, Inc. $196.91 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781029
Principal investigator 1 Insmed, Inc. $200.25 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781031
Principal investigator 1 Insmed, Inc. $20.03 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781035
Principal investigator 1 Insmed, Inc. $174.89 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781043
Principal investigator 1 Insmed, Inc. $267.00 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781047
Principal investigator 1 Insmed, Inc. $33.38 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781053
Principal investigator 1 Insmed, Inc. $44.06 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781055
Principal investigator 1 Insmed, Inc. $200.25 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781057
Principal investigator 1 Insmed, Inc. $53.40 10/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781059
Principal investigator 1 Insmed, Inc. $358.05 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770071
Principal investigator 1 Insmed, Inc. $358.05 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770087
Principal investigator 1 Insmed, Inc. $600.00 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770091
Principal investigator 1 Insmed, Inc. $1,425.58 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770097
Principal investigator 1 Insmed, Inc. $2,403.00 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770117
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774881
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774895
Principal investigator 1 Insmed, Inc. $400.00 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774917
Principal investigator 1 Insmed, Inc. $277.68 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774929
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774931
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774941
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774945
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774947
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774951
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774963
Principal investigator 1 Insmed, Inc. $53.40 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774965
Principal investigator 1 Insmed, Inc. $1,386.53 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775951
Principal investigator 1 Insmed, Inc. $1,563.75 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775957
Principal investigator 1 Insmed, Inc. $1,563.75 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775969
Principal investigator 1 Insmed, Inc. $358.05 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775975
Principal investigator 1 Insmed, Inc. $358.05 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775981
Principal investigator 1 Insmed, Inc. $1,973.47 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776019
Principal investigator 1 Insmed, Inc. $277.68 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780997
Principal investigator 1 Insmed, Inc. $277.68 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781007
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781033
Principal investigator 1 Insmed, Inc. $400.00 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781039
Principal investigator 1 Insmed, Inc. $154.86 10/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781051
Principal investigator 1 Insmed, Inc. $2,160.70 10/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770673
Principal investigator 1 Insmed, Inc. $25.00 10/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770687
Principal investigator 1 Insmed, Inc. $25.00 10/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770689
Principal investigator 1 Insmed, Inc. $620.78 10/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776561
Principal investigator 1 Insmed, Inc. $133.50 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770661
Principal investigator 1 Insmed, Inc. $600.00 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770669
Principal investigator 1 Insmed, Inc. $600.00 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770677
Principal investigator 1 Insmed, Inc. $53.40 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776551
Principal investigator 1 Insmed, Inc. $133.50 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776557
Principal investigator 1 Insmed, Inc. $53.40 08/25/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776563
Principal investigator 1 Insmed, Inc. $400.00 07/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774893
Principal investigator 1 Insmed, Inc. $16,715.25 06/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770035
Principal investigator 1 Insmed, Inc. $2.53 06/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770083
Principal investigator 1 Insmed, Inc. $2.53 06/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774875
Principal investigator 1 Insmed, Inc. $16,715.25 06/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774961
Principal investigator 1 Insmed, Inc. $1,386.53 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770041
Principal investigator 1 Insmed, Inc. $600.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770051
Principal investigator 1 Insmed, Inc. $157.40 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770089
Principal investigator 1 Insmed, Inc. $1,563.75 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770095
Principal investigator 1 Insmed, Inc. $1,425.58 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770099
Principal investigator 1 Insmed, Inc. $1,386.53 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770107
Principal investigator 1 Insmed, Inc. $1,425.58 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770111
Principal investigator 1 Insmed, Inc. $358.05 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770137
Principal investigator 1 Insmed, Inc. $2,028.53 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770655
Principal investigator 1 Insmed, Inc. $1,626.70 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770665
Principal investigator 1 Insmed, Inc. $53.40 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774911
Principal investigator 1 Insmed, Inc. $665.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774955
Principal investigator 1 Insmed, Inc. $665.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774957
Principal investigator 1 Insmed, Inc. $177.22 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775947
Principal investigator 1 Insmed, Inc. $665.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775959
Principal investigator 1 Insmed, Inc. $53.40 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775963
Principal investigator 1 Insmed, Inc. $358.05 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775971
Principal investigator 1 Insmed, Inc. $665.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775977
Principal investigator 1 Insmed, Inc. $358.05 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775983
Principal investigator 1 Insmed, Inc. $400.10 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775995
Principal investigator 1 Insmed, Inc. $358.05 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776001
Principal investigator 1 Insmed, Inc. $2,160.70 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776543
Principal investigator 1 Insmed, Inc. $665.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776571
Principal investigator 1 Insmed, Inc. $620.78 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776577
Principal investigator 1 Insmed, Inc. $800.00 06/26/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781019
Principal investigator 1 AstraZeneca UK Limited $95,563.23 06/19/2023 Non-covered Recipient Entity
THE UNIVERSITY OF KANSAS HEALTH SYSTEM
A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants No dispute reported 06/30/2026 991140783
Principal investigator 1 Insmed, Inc. $23,401.35 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770029
Principal investigator 1 Insmed, Inc. $1.55 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770105
Principal investigator 1 Insmed, Inc. $1.84 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774887
Principal investigator 1 Insmed, Inc. $1.84 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776017
Principal investigator 1 Insmed, Inc. $23,401.35 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781013
Principal investigator 1 Insmed, Inc. $1.55 06/15/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781021
Principal investigator 1 Insmed, Inc. $5.06 05/30/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770127
Principal investigator 1 Insmed, Inc. $5.06 05/30/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774909
Principal investigator 1 Insmed, Inc. $23,401.35 05/30/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774927
Principal investigator 1 Insmed, Inc. $23,401.35 05/30/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776003
Principal investigator 1 Insmed, Inc. $1.33 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770049
Principal investigator 1 Insmed, Inc. $0.46 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770079
Principal investigator 1 Insmed, Inc. $1.33 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774891
Principal investigator 1 Insmed, Inc. $10,029.15 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775949
Principal investigator 1 Insmed, Inc. $10,029.15 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781023
Principal investigator 1 Insmed, Inc. $0.46 05/18/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781037
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $57,337.83 05/08/2023 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 1022141629
Principal investigator 1 Insmed, Inc. $53.40 05/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770121
Principal investigator 1 Insmed, Inc. $600.00 05/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776011
Principal investigator 1 Insmed, Inc. $600.00 05/03/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776013
Principal investigator 1 Insmed, Inc. $2.53 05/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770123
Principal investigator 1 Insmed, Inc. $2.53 05/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774919
Principal investigator 1 Insmed, Inc. $133.50 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770643
Principal investigator 1 Insmed, Inc. $53.40 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770645
Principal investigator 1 Insmed, Inc. $600.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770647
Principal investigator 1 Insmed, Inc. $133.50 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770657
Principal investigator 1 Insmed, Inc. $25.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770663
Principal investigator 1 Insmed, Inc. $25.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770683
Principal investigator 1 Insmed, Inc. $400.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774967
Principal investigator 1 Insmed, Inc. $25.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776547
Principal investigator 1 Insmed, Inc. $25.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776567
Principal investigator 1 Insmed, Inc. $53.40 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780991
Principal investigator 1 Insmed, Inc. $800.00 04/28/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781045
Principal investigator 1 Insmed, Inc. $0.88 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770031
Principal investigator 1 Insmed, Inc. $0.88 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770033
Principal investigator 1 Insmed, Inc. $20,058.30 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770057
Principal investigator 1 Insmed, Inc. $20,058.30 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770077
Principal investigator 1 Insmed, Inc. $20,058.30 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774897
Principal investigator 1 Insmed, Inc. $10,029.15 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775953
Principal investigator 1 Insmed, Inc. $10,029.15 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775991
Principal investigator 1 Insmed, Inc. $0.88 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781005
Principal investigator 1 Insmed, Inc. $10,029.15 04/14/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781049
Principal investigator 1 Insmed, Inc. $23,401.35 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770037
Principal investigator 1 Insmed, Inc. $2.53 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770055
Principal investigator 1 Insmed, Inc. $0.88 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770103
Principal investigator 1 Insmed, Inc. $1.38 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770115
Principal investigator 1 Insmed, Inc. $23,401.35 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775945
Principal investigator 1 Insmed, Inc. $1.38 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775987
Principal investigator 1 Insmed, Inc. $2.53 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776007
Principal investigator 1 Insmed, Inc. $0.88 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776009
Principal investigator 1 Insmed, Inc. $2.53 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780999
Principal investigator 1 Insmed, Inc. $0.88 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781009
Principal investigator 1 Insmed, Inc. $23,401.35 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781025
Principal investigator 1 Insmed, Inc. $1.38 04/05/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781041
Principal investigator 1 Insmed, Inc. $2,063.57 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770039
Principal investigator 1 Insmed, Inc. $2,279.84 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770045
Principal investigator 1 Insmed, Inc. $157.40 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770063
Principal investigator 1 Insmed, Inc. $2,279.84 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770081
Principal investigator 1 Insmed, Inc. $388.09 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770085
Principal investigator 1 Insmed, Inc. $2,403.00 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770113
Principal investigator 1 Insmed, Inc. $1,653.87 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770133
Principal investigator 1 Insmed, Inc. $133.50 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770637
Principal investigator 1 Insmed, Inc. $200.25 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770639
Principal investigator 1 Insmed, Inc. $29.37 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770651
Principal investigator 1 Insmed, Inc. $527.33 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770653
Principal investigator 1 Insmed, Inc. $146.85 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770667
Principal investigator 1 Insmed, Inc. $2,455.73 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770675
Principal investigator 1 Insmed, Inc. $527.33 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770679
Principal investigator 1 Insmed, Inc. $1,544.53 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774877
Principal investigator 1 Insmed, Inc. $1,995.39 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774889
Principal investigator 1 Insmed, Inc. $1,416.57 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774921
Principal investigator 1 Insmed, Inc. $1,653.87 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775943
Principal investigator 1 Insmed, Inc. $1,653.87 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775955
Principal investigator 1 Insmed, Inc. $388.09 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775973
Principal investigator 1 Insmed, Inc. $388.09 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775985
Principal investigator 1 Insmed, Inc. $1,515.69 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775993
Principal investigator 1 Insmed, Inc. $157.40 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775997
Principal investigator 1 Insmed, Inc. $388.09 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776005
Principal investigator 1 Insmed, Inc. $157.40 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978776015
Principal investigator 1 Insmed, Inc. $53.40 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776553
Principal investigator 1 Insmed, Inc. $86.78 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776555
Principal investigator 1 Insmed, Inc. $1,995.16 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776559
Principal investigator 1 Insmed, Inc. $527.33 03/24/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776565
Principal investigator 1 Insmed, Inc. $26,744.40 03/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770059
Principal investigator 1 Insmed, Inc. $1.38 03/08/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770047
Principal investigator 1 Insmed, Inc. $6.33 03/07/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770027
Principal investigator 1 Insmed, Inc. $1.77 03/07/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770101
Principal investigator 1 Insmed, Inc. $26,744.40 03/07/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775961
Principal investigator 1 Insmed, Inc. $25.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770635
Principal investigator 1 Insmed, Inc. $25.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770659
Principal investigator 1 Insmed, Inc. $25.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770671
Principal investigator 1 Insmed, Inc. $665.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774907
Principal investigator 1 Insmed, Inc. $133.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774959
Principal investigator 1 Insmed, Inc. $665.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775965
Principal investigator 1 Insmed, Inc. $665.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775999
Principal investigator 1 Insmed, Inc. $25.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776549
Principal investigator 1 Insmed, Inc. $133.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978780995
Principal investigator 1 Insmed, Inc. $665.00 02/27/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781001
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44.66 02/02/2023 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 1022141635
Principal investigator 1 Insmed, Inc. $444.56 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770065
Principal investigator 1 Insmed, Inc. $133.50 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770069
Principal investigator 1 Insmed, Inc. $600.00 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770109
Principal investigator 1 Insmed, Inc. $53.40 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770135
Principal investigator 1 Insmed, Inc. $600.00 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770649
Principal investigator 1 Insmed, Inc. $53.40 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978770681
Principal investigator 1 Insmed, Inc. $800.00 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978774935
Principal investigator 1 Insmed, Inc. $400.00 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776573
Principal investigator 1 Insmed, Inc. $600.00 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 978776575
Principal investigator 1 Insmed, Inc. $53.40 02/02/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 978781027
Principal investigator 1 Insmed, Inc. $3.80 01/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770075
Principal investigator 1 Insmed, Inc. $26,744.40 01/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770125
Principal investigator 1 Insmed, Inc. $1.11 01/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770139
Principal investigator 1 Insmed, Inc. $0.92 01/20/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775989
Principal investigator 1 Insmed, Inc. $10,029.15 01/17/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770073
Principal investigator 1 Insmed, Inc. $0.88 01/17/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770119
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,447.60 01/13/2023 Non-covered Recipient Entity
UNIV OF KANSAS SW
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 991132031
Principal investigator 1 Insmed, Inc. $26,744.40 01/12/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770053
Principal investigator 1 Insmed, Inc. $3.80 01/12/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978770093
Principal investigator 1 Insmed, Inc. $1.38 01/11/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775979
Principal investigator 1 Insmed, Inc. $1.77 01/04/2023 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 978775967
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7,845.95 01/01/2023 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 1007441233